Soros Fund Management’s Zenas BioPharma ZBIO Stock Holding History

Soros Fund Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-37,500	Closed	-$635K	–	255
2024 Q3	$635K	Buy	+37,500	New	+$674K	0.01%	168

Other funds holding ZBIO

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Federated Hermes

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Soros Fund Management's ZBIO Position: Q4 2024 in Review

Soros Fund Management sold out of Zenas BioPharma (ZBIO) in Q4 2024, closing a stake of 37,500 shares — an estimated $635K sold.

Soros Fund Management first reported a position in ZBIO in Q3 2024 and held it in 1 quarter. The position peaked at $635K in Q3 2024. 65 funds tracked by Wall St. Rank hold ZBIO as of Q4 2024.

Soros Fund Management reported no remaining Zenas BioPharma position as of Q4 2024 after selling out during the quarter.
Soros Fund Management sold 37,500 Zenas BioPharma shares in Q4 2024, an estimated $635K.
Soros Fund Management first reported a position in Zenas BioPharma in Q3 2024 and held it in 1 quarter.
Soros Fund Management's Zenas BioPharma position peaked at $635K in Q3 2024.
65 funds tracked by Wall St. Rank held Zenas BioPharma as of Q4 2024.

Based on Soros Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.